Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Emtricitabine/Tenofovir Alafenamide · Biktarvy, Descovy

Small molecule · Inhibitor of HIV-1 reverse transcriptase · developed by Gilead Sciences

Approved FDA
GILD Developer
3 Registered trials

What is Emtricitabine/Tenofovir Alafenamide?

Emtricitabine/tenofovir alafenamide is a fixed-dose combination of two nucleoside analog reverse transcriptase inhibitors, emtricitabine and tenofovir alafenamide. Both act on HIV-1 reverse transcriptase, competing with natural deoxyribonucleosides for incorporation into viral DNA and causing early chain termination. It is studied in HIV-1 infection and pre-exposure prophylaxis of HIV infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Biktarvy, Descovy, Genvoya, Symtuza
Drug type
Small molecule
Targets
HIV-1 reverse transcriptase
Mechanism
Inhibitor of HIV-1 reverse transcriptase
Pathways
viral DNA synthesis, reverse transcription
Therapy area
Infectious disease
Developer
Gilead Sciences, Inc. (GILD)
FDA status
Approved as Biktarvy, Descovy, Genvoya, NDA208215 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 7, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06337032 Phase 4 HIV-1-infection Recruiting GILD
NCT04994509 Phase 3 Pre-Exposure Prophylaxis of HIV Infection Active not recruiting GILD
NCT07473778 N/A HIV Infections Recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV InfectionsHIV-1-infectionPre-Exposure Prophylaxis of HIV Infection

More from Gilead Sciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Emtricitabine/Tenofovir Alafenamide

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.